Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Allogeneic Gene-modified Gamma Delta T-cells

Cell therapy · Kills target cells · developed by In8bio

Phase 1/2 Most advanced trial
INAB Developer
1 Registered trials

What is Allogeneic Gene-modified Gamma Delta T-cells?

Allogeneic gene-modified gamma delta T-cells are genetically modified donor-derived T-lymphocytes that kill tumor cells directly without MHC-mediated antigen presentation, secrete interferon-gamma, and activate cytotoxic T-lymphocyte responses. They are studied in glioblastoma in combination with temozolomide, to which the genetic modification may confer resistance.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Kills target cells
Pathways
interferon-gamma secretion, cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
In8bio Inc. (INAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05664243 Phase 1/2 Glioblastoma Active not recruiting INAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INAB page.

Follow INAB, the company behind Allogeneic Gene-modified Gamma Delta T-cells

See INAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.